Form 4: OptimizeRx CFO Converts RSUs, Sells Shares for Tax

OptimizeRx's Chief Finance & Strategy Officer, Edward Stelmakh, converted restricted stock units into common stock and subsequently sold a portion to cover tax obligations.

Summary

• Edward Stelmakh, Chief Finance & Strategy Officer of OptimizeRx Corp, reported transactions on December 19, 2025.
• Acquired 5,237 shares of common stock through the conversion of restricted stock units (RSUs) at a price of $0.
• Disposed of 1,388 shares of common stock at $13.51 per share to satisfy tax withholding obligations.
• Following these transactions, Stelmakh beneficially owns 126,830 shares of OptimizeRx common stock.
• The transactions were made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged, non-discretionary sale.

Sentiment

Score: 6

Explanation: The filing reports a routine insider transaction involving RSU conversion and subsequent tax-related share sale. This is a neutral event, slightly positive as it reflects executive compensation vesting, but the sale for tax purposes is standard and not indicative of a negative outlook.

Positives

• Conversion of Restricted Stock Units indicates vesting, which is a positive aspect of the executive's compensation structure.
• The transaction was executed under a Rule 10b5-1 plan, suggesting a pre-planned, non-discretionary sale not based on new material information.

Negatives

• A portion of shares (1,388) was sold, reducing the direct beneficial ownership, although this was explicitly for tax withholding purposes.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders may observe a slight increase in the public float due to the RSU conversion, though the subsequent tax-related sale mitigates this. The overall impact on company valuation or strategy is minimal as this is a routine compensation event.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction where the Chief Finance & Strategy Officer converted restricted stock units and sold a portion to cover tax obligations. Such transactions are common and pre-planned under Rule 10b5-1, indicating no discretionary selling based on new material information. Therefore, this specific filing does not provide a basis for a change in investment recommendation, maintaining a 'hold' stance based on existing company fundamentals.

Keywords

OptimizeRx, OPRX, Edward Stelmakh, Form 4, Insider Transaction, Restricted Stock Units, RSU Conversion, Stock Sale, Tax Withholding, Corporate Officer